Conference Interview #8 of 25
Exploring locoregional recurrence of breast cancer
Liz Meszaros, MDLinx
San Antonio Breast Cancer Symposium 2017
San Antonio, Texas, United States | December 05-09, 2017
The approach, therefore, needs to be individualized, said William Gradishar, MD, professor of medicine, Northwestern University, Evanston, IL.
"The biggest issue that we confront as medical oncologists is once we are aware of a patient who has a locoregional recurrence, more often than not, they have an earlier history of an earlier stage breast cancer, they've gotten some form of adjuvant therapy, and they could very well be many years down the line. Or in particularly aggressive disease, it could be in themidst of their ongoing anti-hormonal adjuvant therapy," said Dr. Gradishar.
"The decision we have to make once it's been diagnosed is whether there's a role for additional different adjuvant therapy," he added. "We have to decide, do all patients need the same type of therapy?"
Dr. Gradishar outlined the further risks in these patients, as well as the differences by cancer subtype in deciding what the optimal therapy should be for each patient.
From this Conference
-
2:34Estrogen receptor expression in luminal tumors & recurrence and metastasisLuminal breast cancer subtypes are characterized by estrogen-receptor and estrogen-related genes, which sets them apart from other tumors that are not hormonally driven.
Angela DeMichele, MD, MSCE -
4:40Implementing the TEAM approach to optimize concurrent palliative careOncologists should be open to implementing the TEAM approach to provide their patients the best concurrent palliative care possible, Thomas J. Smith, MD, FACP, FASCO, FAAHPM,...
Thomas J. Smith, MD, FACP, FASCO, FAAHPM -
1:50Tumor types, immune response, and radiotherapyOne of the most exciting areas of study currently being conducted in breast cancer is the potential of radiation therapy to convert tumors into an in situ vaccine. Silvia...
Silvia Formenti, MD -
1:47Evaluating the risk of breast cancer among female patientsThere are several factors that put female patients at an increased risk for breast cancer.
Amy C. Degnim, MD -
0:52Value of chemotherapy for patients with locoregional breast cancer recurrenceIn patients with locoregional recurrence of breast cancer, the effects of chemotherapy are varied, depending on whether they have hormone receptor positive or hormone receptor...
William Gradishar, MD -
1:50Conversion to response after failed immunotherapyIn some patients with cancer who have failed immune checkpoint blockade treatment, the addition of radiotherapy may bring about conversion to response.
Silvia Formenti, MD
This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium 2017.
